Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Significant Decline in Short Interest

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 148,200 shares, a decline of 14.8% from the November 15th total of 173,900 shares. Approximately 3.0% of the shares of the stock are short sold. Based on an average daily volume of 90,200 shares, the short-interest ratio is presently 1.6 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th.

Brainstorm Cell Therapeutics Stock Up 1.1 %

Shares of BCLI traded up $0.02 during trading hours on Monday, hitting $1.47. The company had a trading volume of 9,468 shares, compared to its average volume of 60,806. The firm has a market cap of $8.36 million, a P/E ratio of -0.30 and a beta of 0.36. The stock’s 50 day moving average price is $1.71 and its 200 day moving average price is $3.85. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.